-
公开(公告)号：US20160376303A1
公开(公告)日：2016-12-29
申请号：US15038970
申请日：2014-11-20
发明人： Hideyuki Takeuchi , Akio Suzumura
IPC分类号： C07J63/00
CPC分类号： C07J63/008
摘要： A novel glycyrrhetinic acid derivative. The glycyrrhetinic acid derivative is represented by the following general formula.
摘要翻译： 公开了一种新的甘草次酸衍生物。 甘草次酸衍生物由以下通式（1）表示。
-
公开(公告)号：US09796751B2
公开(公告)日：2017-10-24
申请号：US15038970
申请日：2014-11-20
发明人： Hideyuki Takeuchi , Akio Suzumura
CPC分类号： C07J63/008
摘要： A novel glycyrrhetinic acid derivative. The glycyrrhetinic acid derivative is represented by the following general formula.
-
公开(公告)号：US20090304712A1
公开(公告)日：2009-12-10
申请号：US12223472
申请日：2007-02-01
申请人： Hideyuki Takeuchi , Akio Suzumura
发明人： Hideyuki Takeuchi , Akio Suzumura
IPC分类号： A61K39/395 , G01N33/553 , A61P25/00
CPC分类号： A61K31/135 , A61K31/198 , A61K31/22 , A61K31/56 , C07K16/241 , C07K16/2878 , C07K2317/76
摘要： A neuronal cell death inhibitor comprising a compound having an inhibitory activity on the production and/or release of glutamic acid in a microglia; by inhibiting the production and/or release in a microglia, neurite bead-like degeneration or neuronal cell death can be inhibited.
摘要翻译： 一种神经元细胞死亡抑制剂，其包含对小胶质细胞中谷氨酸的产生和/或释放具有抑制活性的化合物; 通过抑制小胶质细胞的产生和/或释放，可以抑制神经突珠样变性或神经元细胞死亡。
-
公开(公告)号：US20110190354A1
公开(公告)日：2011-08-04
申请号：US13054161
申请日：2009-07-15
申请人： Hideyuki Takeuchi , Akio Suzumura
发明人： Hideyuki Takeuchi , Akio Suzumura
IPC分类号： A61K31/455 , C07D213/80 , A61P25/00
CPC分类号： A61K31/194
摘要： Disclosed is a gap junction inhibitor which is more practically useful compared with carbenoxolone. Also disclosed is a novel glycyrrhetinic acid derivative. The glycyrrhetinic acid derivative is represented by general formula (1) or (2).
摘要翻译： 公开了间隙连接抑制剂，其与carbenoxolone相比更实际有用。 还公开了一种新型的甘草次酸衍生物。 甘草次酸衍生物由通式（1）或（2）表示。
-
公开(公告)号：US08378112B2
公开(公告)日：2013-02-19
申请号：US13054161
申请日：2009-07-15
申请人： Hideyuki Takeuchi , Akio Suzumura
发明人： Hideyuki Takeuchi , Akio Suzumura
IPC分类号： A61K31/455 , A61P25/00 , C07D213/80
CPC分类号： A61K31/194
摘要： Disclosed is a gap junction inhibitor which is more practically useful compared with carbenoxolone. Also disclosed is a novel glycyrrhetinic acid derivative. The glycyrrhetinic acid derivative is represented by general formula (1) or (2).
摘要翻译： 公开了间隙连接抑制剂，其与carbenoxolone相比更实际有用。 还公开了一种新型的甘草次酸衍生物。 甘草次酸衍生物由通式（1）或（2）表示。
-
公开(公告)号：US20100197726A1
公开(公告)日：2010-08-05
申请号：US12669865
申请日：2008-07-18
申请人： Akio Suzumura
发明人： Akio Suzumura
IPC分类号： A61K31/47 , C07D215/04 , A61P3/10 , A61P19/02
CPC分类号： A61K31/47 , C07D215/14
摘要： The present invention is to provide an inhibitor that inhibits differentiation of T cells into Th1 cells.The inhibitor that inhibits differentiation of T cells into Th1 cells contains, as an active ingredient, pitavastatin or a salt thereof.
摘要翻译： 本发明提供抑制T细胞分化为Th1细胞的抑制剂。 抑制T细胞分化为Th1细胞的抑制剂作为活性成分含有匹伐他汀或其盐。
-
公开(公告)号：US20060093578A1
公开(公告)日：2006-05-04
申请号：US11266409
申请日：2005-11-04
申请人： Akio Suzumura
发明人： Akio Suzumura
IPC分类号： A61K38/21 , A61K31/519
CPC分类号： A61K31/519 , A61K38/215 , A61K45/06 , A61K2300/00
摘要： A method of treating multiple sclerosis including administering Interferon-β and a phosphodiesterase inhibitor in combination in a therapeutically effective amount.
摘要翻译： 一种治疗多发性硬化症的方法，包括以治疗有效量组合施用干扰素-β和磷酸二酯酶抑制剂。
-
8.发明授权Methods for treatment or prevention of diseases associated with functional disorder of regulatory T cells 失效治疗或预防与调节性T细胞功能紊乱相关的疾病的方法公开(公告)号：US08716230B2
公开(公告)日：2014-05-06
申请号：US12902389
申请日：2010-10-12
申请人： Akio Suzumura , Jinyan Wang , Takashi Matsui , Sadatoshi Sakuma , Shin Miyakawa , Masatoshi Fujiwara , Yoshikazu Nakamura
发明人： Akio Suzumura , Jinyan Wang , Takashi Matsui , Sadatoshi Sakuma , Shin Miyakawa , Masatoshi Fujiwara , Yoshikazu Nakamura
IPC分类号： A61K51/08 , A61K31/7088 , C07K2/00 , C07H21/04
CPC分类号： C07K16/22 , A61K31/7105 , A61K31/711 , A61K2039/505 , C07K2317/76 , G01N33/505 , G01N2333/475 , G01N2500/04
摘要： The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by inhibiting MK expression or its activity, thereby increasing the number of regulatory T cells. Furthermore, it was found that diseases associated with the functional disorder of regulatory T cells can be treated with the administration of an inhibitor that inhibits MK expression or activity.
摘要翻译： 发明人研究了MK在实验性自身免疫性脑脊髓炎中的作用，其是多发性硬化症的人类模型。 结果发现MK具有抑制调节性T细胞的作用，通过抑制MK表达或其活性可以抑制1型辅助性T细胞诱导的自身免疫机制，从而增加调节性T细胞的数量。 此外，发现与调节性T细胞的功能障碍相关的疾病可以通过施用抑制MK表达或活性的抑制剂来治疗。
-
9.发明授权Method for treatment or prevention of disease associated with functional disorder of regulatory T cell 有权治疗或预防与调节性T细胞功能紊乱相关的疾病的方法公开(公告)号：US08128934B2
公开(公告)日：2012-03-06
申请号：US12084907
申请日：2006-11-14
申请人： Akio Suzumura , Jinyan Wang , Takashi Matsui , Sadatoshi Sakuma , Shin Miyakawa , Masatoshi Fujiwara , Yoshikazu Nakamura
发明人： Akio Suzumura , Jinyan Wang , Takashi Matsui , Sadatoshi Sakuma , Shin Miyakawa , Masatoshi Fujiwara , Yoshikazu Nakamura
IPC分类号： A61K39/395 , C07K16/22
CPC分类号： C07K16/22 , A61K31/7105 , A61K31/711 , A61K2039/505 , C07K2317/76 , G01N33/505 , G01N2333/475 , G01N2500/04
摘要： The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by inhibiting MK expression or its activity, thereby increasing the number of regulatory T cells. Furthermore, it was found that diseases associated with the functional disorder of regulatory T cells can be treated with the administration of an inhibitor that inhibits MK expression or activity.
摘要翻译： 发明人研究了MK在实验性自身免疫性脑脊髓炎中的作用，其是多发性硬化症的人类模型。 结果发现MK具有抑制调节性T细胞的作用，通过抑制MK表达或其活性可以抑制1型辅助性T细胞诱导的自身免疫机制，从而增加调节性T细胞的数量。 此外，发现与调节性T细胞的功能障碍相关的疾病可以通过施用抑制MK表达或活性的抑制剂来治疗。
-
10.发明申请Method for Treatment or Prevention of Disease Associated Wtih Functional Disorder of Regulatory T Cell 有权治疗或预防调节性T细胞疾病相关性功能障碍的方法公开(公告)号：US20100092488A1
公开(公告)日：2010-04-15
申请号：US12084907
申请日：2006-11-14
申请人： Akio Suzumura , Jinyan Wang , Takashi Matsui , Sadatoshi Sakuma , Shin Miyakawa , Masatoshi Fujiwara , Yoshikazu Nakamura
发明人： Akio Suzumura , Jinyan Wang , Takashi Matsui , Sadatoshi Sakuma , Shin Miyakawa , Masatoshi Fujiwara , Yoshikazu Nakamura
IPC分类号： A61K39/395 , C12Q1/68 , A61K31/7105 , A61P37/06 , A61P25/28 , A61K31/711
CPC分类号： C07K16/22 , A61K31/7105 , A61K31/711 , A61K2039/505 , C07K2317/76 , G01N33/505 , G01N2333/475 , G01N2500/04
摘要： The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by inhibiting MK expression or its activity, thereby increasing the number of regulatory T cells. Furthermore, it was found that diseases associated with the functional disorder of regulatory T cells can be treated with the administration of an inhibitor that inhibits MK expression or activity.
摘要翻译： 发明人研究了MK在实验性自身免疫性脑脊髓炎中的作用，其是多发性硬化症的人类模型。 结果发现MK具有抑制调节性T细胞的作用，通过抑制MK表达或其活性可以抑制1型辅助性T细胞诱导的自身免疫机制，从而增加调节性T细胞的数量。 此外，发现与调节性T细胞的功能障碍相关的疾病可以通过施用抑制MK表达或活性的抑制剂来治疗。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.02 秒)
